Achievement of Treat-to-Target Thresholds with Envudeucitinib, a Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Results from STRIDE and OLE. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s650, 2025. DOI: 10.25251/8xwzce61. Disponível em: https://skin.dermsquared.com/skin/article/view/3905. Acesso em: 2 may. 2026.